Source:http://linkedlifedata.com/resource/pubmed/id/17563398
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0011145,
umls-concept:C0033640,
umls-concept:C0037083,
umls-concept:C0085862,
umls-concept:C0087111,
umls-concept:C0450442,
umls-concept:C0871261,
umls-concept:C1299583,
umls-concept:C1549571,
umls-concept:C1608386,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1710082,
umls-concept:C2911692
|
pubmed:issue |
6
|
pubmed:dateCreated |
2007-6-12
|
pubmed:abstractText |
Protein kinase C (PKC) plays a critical role in diseases such as cancer, stroke, and cardiac ischemia and participates in a variety of signal transduction pathways including apoptosis, cell proliferation, and tumor suppression. Here, we demonstrate that PKCdelta is proteolytically cleaved and translocated to the nucleus in a time-dependent manner on treatment of desferroxamine (DFO), a hypoxia-mimetic agent. Specific knockdown of the endogenous PKCdelta by RNAi (sh-PKCdelta) or expression of the kinase-dead (Lys376Arg) mutant of PKCdelta (PKCdeltaKD) conferred modulation on the cellular adaptive responses to DFO treatment. Notably, the time-dependent accumulation of DFO-induced phosphorylation of Ser-139-H2AX (gamma-H2AX), a hallmark for DNA damage, was altered by sh-PKCdelta, and sh-PKCdelta completely abrogated the activation of caspase-3 in DFO-treated cells. Expression of Lys376Arg-mutated PKCdelta-enhanced green fluorescent protein (EGFP) appears to abrogate DFO/hypoxia-induced activation of endogenous PKCdelta and caspase-3, suggesting that PKCdeltaKD-EGFP serves a dominant-negative function. Additionally, DFO treatment also led to the activation of Chk1, p53, and Akt, where DFO-induced activation of p53, Chk1, and Akt occurred in both PKCdelta-dependent and -independent manners. In summary, these findings suggest that the activation of a PKCdelta-mediated signaling network is one of the critical contributing factors involved in fine-tuning of the DNA damage response to DFO treatment.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0363-6143
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
292
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
C2150-60
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:17563398-Active Transport, Cell Nucleus,
pubmed-meshheading:17563398-Animals,
pubmed-meshheading:17563398-Anoxia,
pubmed-meshheading:17563398-Caspase 3,
pubmed-meshheading:17563398-Cell Line,
pubmed-meshheading:17563398-DNA Damage,
pubmed-meshheading:17563398-Deferoxamine,
pubmed-meshheading:17563398-Epithelial Cells,
pubmed-meshheading:17563398-Oncogene Protein v-akt,
pubmed-meshheading:17563398-Protein Kinase C-delta,
pubmed-meshheading:17563398-Rats,
pubmed-meshheading:17563398-Signal Transduction
|
pubmed:year |
2007
|
pubmed:articleTitle |
Protein kinase Cdelta-dependent and -independent signaling in genotoxic response to treatment of desferroxamine, a hypoxia-mimetic agent.
|
pubmed:affiliation |
Department of Molecular Pharmacology, University of Southern California, Los Angeles, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|